Dated disclosed rounds · latest 2023-01-01
Series B
Grey Wolf Therapeutics
Immuno-oncology
VerifiedSeries BOxford
- Companies House
- 10989365
- GLEIF LEI
- Not matched
- Latest evidence
- 2023-01-01
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-01
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
3 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series B
£39.5M · 2 named investors
RegistryRegistry fact Company incorporated
GREY WOLF THERAPEUTICS LIMITED · company 10989365
Latest disclosed round
Series B
- Date
- 2023-01-01
- Amount
- GBP 39.5m
- Sector
- Biotech & techbio
- Companies House
- 10989365
- ONS region
- South East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
2 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| British Patient Capital | participant | 2023-01-01 | Sifted ↗ · Sifted ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Oxford Science Enterprises | participant | 2026-08-25 | Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
1 disclosed round
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2023-01-01 | Series B | £39.5M | 2 additional source-listed names | Sifted ↗ · Sifted ↗ |
Companies House status and filing snapshot
GREY WOLF THERAPEUTICS LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2017-09-29
- Dissolved
- Not applicable
- Company number
- 10989365
Filing context
- Accounts category
- SMALL
- Accounts made up to
- 2024-12-31
- Next accounts due
- 2026-09-30
- Confirmation made up to
- 2025-10-27
- Registry snapshot
- 2026-08-01
- Live check
- Bulk snapshot only
72110Research and experimental development on biotechnology
Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.